Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

RGD-decorated cholesterol stabilized polyplexes for targeted siRNA delivery to glioblastoma cells.

Lou B, Connor K, Sweeney K, Miller IS, O'Farrell A, Ruiz-Hernandez E, Murray DM, Duffy GP, Wolfe A, Mastrobattista E, Byrne AT, Hennink WE.

Drug Deliv Transl Res. 2019 Jun;9(3):679-693. doi: 10.1007/s13346-019-00637-y.

PMID:
30972664
2.

When RON MET TAM in Mesothelioma: All Druggable for One, and One Drug for All?

Baird AM, Easty D, Jarzabek M, Shiels L, Soltermann A, Klebe S, Raeppel S, MacDonagh L, Wu C, Griggs K, Kirschner MB, Stanfill B, Nonaka D, Goparaju CM, Murer B, Fennell DA, O'Donnell DM, Barr MP, Mutti L, Reid G, Finn S, Cuffe S, Pass HI, Opitz I, Byrne AT, O'Byrne KJ, Gray SG.

Front Endocrinol (Lausanne). 2019 Feb 26;10:89. doi: 10.3389/fendo.2019.00089. eCollection 2019.

3.

Implementing Reverse Phase Protein Array Profiling as a Sensitive Method for the Early Pre-Clinical Detection of Off-Target Toxicities Associated with Sunitinib Malate.

O'Farrell AC, Miller IS, Evans R, Alamanou M, Cary M, Mallya Udupi G, Lafferty A, Monsefi N, Cremona M, Prehn JHM, Verheul HM, Gallagher WM, Gehrmann M, Byrne AT.

Proteomics Clin Appl. 2019 Feb 15:e1800159. doi: 10.1002/prca.201800159. [Epub ahead of print]

PMID:
30768761
4.

A review of filamin A mutations and associated interstitial lung disease.

Sasaki E, Byrne AT, Phelan E, Cox DW, Reardon W.

Eur J Pediatr. 2019 Feb;178(2):121-129. doi: 10.1007/s00431-018-3301-0. Epub 2018 Dec 13. Review.

PMID:
30547349
5.

Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy.

Smeets D, Miller IS, O'Connor DP, Das S, Moran B, Boeckx B, Gaiser T, Betge J, Barat A, Klinger R, van Grieken NCT, Cremolini C, Prenen H, Mazzone M, Depreeuw J, Bacon O, Fender B, Brady J, Hennessy BT, McNamara DA, Kay E, Verheul HM, Maarten N, Gallagher WM, Murphy V, Prehn JHM, Koopman M, Punt CJA, Loupakis F, Ebert MPA, Ylstra B, Lambrechts D, Byrne AT.

Nat Commun. 2018 Oct 5;9(1):4112. doi: 10.1038/s41467-018-06567-6.

6.

Author Correction: Anti-angiogenic drug scheduling optimisation with application to colorectal cancer.

Sturrock M, Miller IS, Kang G, Arba'ie NH, O'Farrell AC, Barat A, Marston G, Coletta PL, Byrne AT, Prehn JH.

Sci Rep. 2018 Sep 27;8(1):14705. doi: 10.1038/s41598-018-31456-9.

7.

Anti-angiogenic drug scheduling optimisation with application to colorectal cancer.

Sturrock M, Miller IS, Kang G, Hannis Arba'ie N, O'Farrell AC, Barat A, Marston G, Coletta PL, Byrne AT, Prehn JH.

Sci Rep. 2018 Jul 25;8(1):11182. doi: 10.1038/s41598-018-29318-5. Erratum in: Sci Rep. 2018 Sep 27;8(1):14705.

8.

Interrogation of transcriptomic changes associated with drug-induced hepatic sinusoidal dilatation in colorectal cancer.

Jarzabek MA, Proctor WR, Vogt J, Desai R, Dicker P, Cain G, Raja R, Brodbeck J, Stevens D, van der Stok EP, Martens JWM, Verhoef C, Hegde PS, Byrne AT, Tarrant JM.

PLoS One. 2018 Jun 7;13(6):e0198099. doi: 10.1371/journal.pone.0198099. eCollection 2018.

9.

Loss of Chromosome 18q11.2-q12.1 Is Predictive for Survival in Patients With Metastatic Colorectal Cancer Treated With Bevacizumab.

van Dijk E, Biesma HD, Cordes M, Smeets D, Neerincx M, Das S, Eijk PP, Murphy V, Barat A, Bacon O, Prehn JHM, Betge J, Gaiser T, Fender B, Meijer GA, McNamara DA, Klinger R, Koopman M, Ebert MPA, Kay EW, Hennessey BT, Verheul HMW, Gallagher WM, O'Connor DP, Punt CJA, Loupakis F, Lambrechts D, Byrne AT, van Grieken NCT, Ylstra B.

J Clin Oncol. 2018 Jul 10;36(20):2052-2060. doi: 10.1200/JCO.2017.77.1782. Epub 2018 May 24.

PMID:
29792754
10.

PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models.

Meehan TF, Conte N, Goldstein T, Inghirami G, Murakami MA, Brabetz S, Gu Z, Wiser JA, Dunn P, Begley DA, Krupke DM, Bertotti A, Bruna A, Brush MH, Byrne AT, Caldas C, Christie AL, Clark DA, Dowst H, Dry JR, Doroshow JH, Duchamp O, Evrard YA, Ferretti S, Frese KK, Goodwin NC, Greenawalt D, Haendel MA, Hermans E, Houghton PJ, Jonkers J, Kemper K, Khor TO, Lewis MT, Lloyd KCK, Mason J, Medico E, Neuhauser SB, Olson JM, Peeper DS, Rueda OM, Seong JK, Trusolino L, Vinolo E, Wechsler-Reya RJ, Weinstock DM, Welm A, Weroha SJ, Amant F, Pfister SM, Kool M, Parkinson H, Butte AJ, Bult CJ.

Cancer Res. 2017 Nov 1;77(21):e62-e66. doi: 10.1158/0008-5472.CAN-17-0582.

11.

Interrogating open issues in cancer medicine with patient-derived xenografts.

Byrne AT, Alférez DG, Amant F, Annibali D, Arribas J, Biankin AV, Bruna A, Budinská E, Caldas C, Chang DK, Clarke RB, Clevers H, Coukos G, Dangles-Marie V, Eckhardt SG, Gonzalez-Suarez E, Hermans E, Hidalgo M, Jarzabek MA, de Jong S, Jonkers J, Kemper K, Lanfrancone L, Mælandsmo GM, Marangoni E, Marine JC, Medico E, Norum JH, Palmer HG, Peeper DS, Pelicci PG, Piris-Gimenez A, Roman-Roman S, Rueda OM, Seoane J, Serra V, Soucek L, Vanhecke D, Villanueva A, Vinolo E, Bertotti A, Trusolino L.

Nat Rev Cancer. 2017 Sep 15;17(10):632. doi: 10.1038/nrc.2017.85. [Epub ahead of print]

PMID:
28912576
12.

Assessment of concordance between fresh-frozen and formalin-fixed paraffin embedded tumor DNA methylation using a targeted sequencing approach.

Moran B, Das S, Smeets D, Peutman G, Klinger R, Fender B, Connor K, Ebert M, Gaiser T, Prehn JH, Bacon O, Kay E, Hennessy B, Murphy V, Ylstra B, Lambrechts D, Byrne AT, Gallagher WM, O'Connor DP.

Oncotarget. 2017 Jul 18;8(29):48126-48137. doi: 10.18632/oncotarget.18296.

13.

Apelin: A putative novel predictive biomarker for bevacizumab response in colorectal cancer.

Zuurbier L, Rahman A, Cordes M, Scheick J, Wong TJ, Rustenburg F, Joseph JC, Dynoodt P, Casey R, Drillenburg P, Gerhards M, Barat A, Klinger R, Fender B, O'Connor DP, Betge J, Ebert MP, Gaiser T, Prehn JHM, Griffioen AW, van Grieken NCT, Ylstra B, Byrne AT, van der Flier LG, Gallagher WM, Postel R.

Oncotarget. 2017 Jun 27;8(26):42949-42961. doi: 10.18632/oncotarget.17306.

14.

A Novel Positron Emission Tomography (PET) Approach to Monitor Cardiac Metabolic Pathway Remodeling in Response to Sunitinib Malate.

O'Farrell AC, Evans R, Silvola JM, Miller IS, Conroy E, Hector S, Cary M, Murray DW, Jarzabek MA, Maratha A, Alamanou M, Udupi GM, Shiels L, Pallaud C, Saraste A, Liljenbäck H, Jauhiainen M, Oikonen V, Ducret A, Cutler P, McAuliffe FM, Rousseau JA, Lecomte R, Gascon S, Arany Z, Ky B, Force T, Knuuti J, Gallagher WM, Roivainen A, Byrne AT.

PLoS One. 2017 Jan 27;12(1):e0169964. doi: 10.1371/journal.pone.0169964. eCollection 2017.

15.

Interrogating open issues in cancer precision medicine with patient-derived xenografts.

Byrne AT, Alférez DG, Amant F, Annibali D, Arribas J, Biankin AV, Bruna A, Budinská E, Caldas C, Chang DK, Clarke RB, Clevers H, Coukos G, Dangles-Marie V, Eckhardt SG, Gonzalez-Suarez E, Hermans E, Hidalgo M, Jarzabek MA, de Jong S, Jonkers J, Kemper K, Lanfrancone L, Mælandsmo GM, Marangoni E, Marine JC, Medico E, Norum JH, Palmer HG, Peeper DS, Pelicci PG, Piris-Gimenez A, Roman-Roman S, Rueda OM, Seoane J, Serra V, Soucek L, Vanhecke D, Villanueva A, Vinolo E, Bertotti A, Trusolino L.

Nat Rev Cancer. 2017 Apr;17(4):254-268. doi: 10.1038/nrc.2016.140. Epub 2017 Jan 20. Review. Erratum in: Nat Rev Cancer. 2017 Sep 15;:.

16.

Outcome of Colorectal Cancer Patients Treated with Combination Bevacizumab Therapy: A Pooled Retrospective Analysis of Three European Cohorts from the Angiopredict Initiative.

Betge J, Barat A, Murphy V, Hielscher T, Van Grieken NC, Belle S, Zhan T, Härtel N, Kripp M, Bacon O, Cordes M, Kay EW, Verheul HM, Neerincx M, Hennessy B, Hofheinz RD, Gaiser T, Ylstra B, Prehn JH, Lambrechts D, Byrne AT, Ebert MP, Schulte N.

Digestion. 2016;94(3):129-137. doi: 10.1159/000449412. Epub 2016 Oct 19.

PMID:
27756074
17.

AKT1 (E17K) mutation profiling in breast cancer: prevalence, concurrent oncogenic alterations, and blood-based detection.

Rudolph M, Anzeneder T, Schulz A, Beckmann G, Byrne AT, Jeffers M, Pena C, Politz O, Köchert K, Vonk R, Reischl J.

BMC Cancer. 2016 Aug 11;16:622. doi: 10.1186/s12885-016-2626-1.

18.

The IL-17-Th1/Th17 pathway: an attractive target for lung cancer therapy?

Joerger M, Finn SP, Cuffe S, Byrne AT, Gray SG.

Expert Opin Ther Targets. 2016 Nov;20(11):1339-1356. Epub 2016 Jul 11. Review.

PMID:
27353429
19.

Modelling tumour cell proliferation from vascular structure using tissue decomposition into avascular elements.

Besenhard MO, Jarzabek M, O'Farrell AC, Callanan JJ, Prehn JH, Byrne AT, Huber HJ.

J Theor Biol. 2016 Aug 7;402:129-43. doi: 10.1016/j.jtbi.2016.04.028. Epub 2016 May 5.

PMID:
27155046
20.

Targeting the 19S proteasomal subunit, Rpt4, for the treatment of colon cancer.

Boland K, Flanagan L, McCawley N, Pabari R, Kay EW, McNamara DA, Murray F, Byrne AT, Ramtoola Z, Concannon CG, Prehn JH.

Eur J Pharmacol. 2016 Jun 5;780:53-64. doi: 10.1016/j.ejphar.2016.03.031. Epub 2016 Mar 17.

PMID:
26997367
21.

Mechanistic interrogation of combination bevacizumab/dual PI3K/mTOR inhibitor response in glioblastoma implementing novel MR and PET imaging biomarkers.

O'Halloran PJ, Viel T, Murray DW, Wachsmuth L, Schwegmann K, Wagner S, Kopka K, Jarzabek MA, Dicker P, Hermann S, Faber C, Klasen T, Schäfers M, O'Brien D, Prehn JH, Jacobs AH, Byrne AT.

Eur J Nucl Med Mol Imaging. 2016 Aug;43(9):1673-83. doi: 10.1007/s00259-016-3343-3. Epub 2016 Mar 15.

PMID:
26975402
22.

Patient-derived glioblastoma cells show significant heterogeneity in treatment responses to the inhibitor-of-apoptosis-protein antagonist birinapant.

Zakaria Z, Tivnan A, Flanagan L, Murray DW, Salvucci M, Stringer BW, Day BW, Boyd AW, Kögel D, Rehm M, O'Brien DF, Byrne AT, Prehn JH.

Br J Cancer. 2016 Jan 19;114(2):188-98. doi: 10.1038/bjc.2015.420. Epub 2015 Dec 10.

23.

A Paediatric Hernia with a Twist: The Presentation, Imaging Findings and Management of a Strangulated Ovarian Hernia.

Hughes P, Abdelhafeez A, Byrne AT, Real D, Gillick J.

Ir Med J. 2015 Oct;108(9):282-3.

PMID:
26625655
24.

The chain length of biologically produced (R)-3-hydroxyalkanoic acid affects biological activity and structure of anti-cancer peptides.

Szwej E, Devocelle M, Kenny S, Guzik M, O'Connor S, Nikodinovic-Runic J, Radivojevic J, Maslak V, Byrne AT, Gallagher WM, Zulian QR, Zinn M, O'Connor KE.

J Biotechnol. 2015 Jun 20;204:7-12. doi: 10.1016/j.jbiotec.2015.02.036. Epub 2015 Mar 24.

PMID:
25820126
25.

Integrating Colon Cancer Microarray Data: Associating Locus-Specific Methylation Groups to Gene Expression-Based Classifications.

Barat A, Ruskin HJ, Byrne AT, Prehn JH.

Microarrays (Basel). 2015 Nov 23;4(4):630-46. doi: 10.3390/microarrays4040630.

26.

Comparison of performance in a four year graduate entry medical programme and a traditional five/six year programme.

Byrne AT, Arnett R, Farrell T, Sreenan S.

BMC Med Educ. 2014 Dec 10;14:248. doi: 10.1186/s12909-014-0248-3.

27.

Interrogation of gossypol therapy in glioblastoma implementing cell line and patient-derived tumour models.

Jarzabek MA, Amberger-Murphy V, Callanan JJ, Gao C, Zagozdzon AM, Shiels L, Wang J, Ligon KL, Rich BE, Dicker P, Gallagher WM, Prehn JH, Byrne AT.

Br J Cancer. 2014 Dec 9;111(12):2275-86. doi: 10.1038/bjc.2014.529. Epub 2014 Nov 6.

28.

Patient-derived xenograft models: an emerging platform for translational cancer research.

Hidalgo M, Amant F, Biankin AV, Budinská E, Byrne AT, Caldas C, Clarke RB, de Jong S, Jonkers J, Mælandsmo GM, Roman-Roman S, Seoane J, Trusolino L, Villanueva A.

Cancer Discov. 2014 Sep;4(9):998-1013. doi: 10.1158/2159-8290.CD-14-0001. Epub 2014 Jul 15. Review.

29.

Validation of an imageable surgical resection animal model of Glioblastoma (GBM).

Sweeney KJ, Jarzabek MA, Dicker P, O'Brien DF, Callanan JJ, Byrne AT, Prehn JH.

J Neurosci Methods. 2014 Aug 15;233:99-104. doi: 10.1016/j.jneumeth.2014.05.006. Epub 2014 Jun 18.

PMID:
24952322
30.

Neuromedin U: a candidate biomarker and therapeutic target to predict and overcome resistance to HER-tyrosine kinase inhibitors.

Rani S, Corcoran C, Shiels L, Germano S, Breslin S, Madden S, McDermott MS, Browne BC, O'Donovan N, Crown J, Gogarty M, Byrne AT, O'Driscoll L.

Cancer Res. 2014 Jul 15;74(14):3821-33. doi: 10.1158/0008-5472.CAN-13-2053. Epub 2014 May 29.

31.

Comparison of anthropometric-based equations for estimation of body fat percentage in a normal-weight and overweight female cohort: validation via air-displacement plethysmography.

Temple D, Denis R, Walsh MC, Dicker P, Byrne AT.

Public Health Nutr. 2015 Feb;18(3):446-52. doi: 10.1017/S1368980014000597. Epub 2014 Apr 16.

PMID:
24735997
32.

Guanine nucleotide exchange factor Dock7 mediates HGF-induced glioblastoma cell invasion via Rac activation.

Murray DW, Didier S, Chan A, Paulino V, Van Aelst L, Ruggieri R, Tran NL, Byrne AT, Symons M.

Br J Cancer. 2014 Mar 4;110(5):1307-15. doi: 10.1038/bjc.2014.39. Epub 2014 Feb 11.

33.

Molecular imaging in the development of a novel treatment paradigm for glioblastoma (GBM): an integrated multidisciplinary commentary.

Jarzabek MA, Sweeney KJ, Evans RL, Jacobs AH, Stupp R, O'Brien D, Berger MS, Prehn JH, Byrne AT.

Drug Discov Today. 2013 Nov;18(21-22):1052-66. doi: 10.1016/j.drudis.2013.06.004. Epub 2013 Jun 20. Review.

PMID:
23792334
34.

In vivo bioluminescence imaging validation of a human biopsy-derived orthotopic mouse model of glioblastoma multiforme.

Jarzabek MA, Huszthy PC, Skaftnesmo KO, McCormack E, Dicker P, Prehn JH, Bjerkvig R, Byrne AT.

Mol Imaging. 2013 May;12(3):161-72.

PMID:
23490442
35.

The anti-cancer activity of a cationic anti-microbial peptide derived from monomers of polyhydroxyalkanoate.

O'Connor S, Szwej E, Nikodinovic-Runic J, O'Connor A, Byrne AT, Devocelle M, O'Donovan N, Gallagher WM, Babu R, Kenny ST, Zinn M, Zulian QR, O'Connor KE.

Biomaterials. 2013 Apr;34(11):2710-8. doi: 10.1016/j.biomaterials.2012.12.032. Epub 2013 Jan 21.

PMID:
23343631
36.

Staphylococcus aureus nasal septal abscess complicated by extradural abscess in an infant.

Tan NW, Turvey SE, Byrne AT, Ludemann JP, Kollmann TR.

J Otolaryngol Head Neck Surg. 2012 Feb;41(1):E7-12. No abstract available.

PMID:
22498276
37.

Natural history of untreated syringomyelia in pediatric patients.

Singhal A, Bowen-Roberts T, Steinbok P, Cochrane D, Byrne AT, Kerr JM.

Neurosurg Focus. 2011 Dec;31(6):E13. doi: 10.3171/2011.9.FOCUS11208.

PMID:
22133172
38.

Examining the role of Rac1 in tumor angiogenesis and growth: a clinically relevant RNAi-mediated approach.

Vader P, van der Meel R, Symons MH, Fens MH, Pieters E, Wilschut KJ, Storm G, Jarzabek M, Gallagher WM, Schiffelers RM, Byrne AT.

Angiogenesis. 2011 Dec;14(4):457-66. doi: 10.1007/s10456-011-9229-x. Epub 2011 Jul 26.

PMID:
21789714
39.

Diffusion-weighted imaging and pathological correlation in pediatric medulloblastomas-"They are not always restricted!".

Pillai S, Singhal A, Byrne AT, Dunham C, Cochrane DD, Steinbok P.

Childs Nerv Syst. 2011 Sep;27(9):1407-11. doi: 10.1007/s00381-011-1499-5. Epub 2011 Jul 6.

PMID:
21732119
40.

Mechanism of cell death mediated by a BF2-chelated tetraaryl-azadipyrromethene photodynamic therapeutic: dissection of the apoptotic pathway in vitro and in vivo.

O'Connor AE, Mc Gee MM, Likar Y, Ponomarev V, Callanan JJ, O'shea DF, Byrne AT, Gallagher WM.

Int J Cancer. 2012 Feb 1;130(3):705-15. doi: 10.1002/ijc.26073. Epub 2011 May 26.

41.

The VEGF/Rho GTPase signalling pathway: a promising target for anti-angiogenic/anti-invasion therapy.

van der Meel R, Symons MH, Kudernatsch R, Kok RJ, Schiffelers RM, Storm G, Gallagher WM, Byrne AT.

Drug Discov Today. 2011 Mar;16(5-6):219-28. doi: 10.1016/j.drudis.2011.01.005. Epub 2011 Jan 22. Review.

PMID:
21262381
42.

Microfibrillar collagen hemostat-induced necrotizing granulomatous inflammation developing after craniotomy: a pediatric case series.

Apel-Sarid L, Cochrane DD, Steinbok P, Byrne AT, Dunham C.

J Neurosurg Pediatr. 2010 Oct;6(4):385-92. doi: 10.3171/2010.8.PEDS10248.

PMID:
20887115
43.

Synergistic interaction between trastuzumab and EGFR/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cells.

O'Donovan N, Byrne AT, O'Connor AE, McGee S, Gallagher WM, Crown J.

Invest New Drugs. 2011 Oct;29(5):752-9. doi: 10.1007/s10637-010-9415-5. Epub 2010 Mar 16.

PMID:
20229355
44.

Erythrophagocytosis by angiogenic endothelial cells is enhanced by loss of erythrocyte deformability.

Fens MH, Storm G, Pelgrim RC, Ultee A, Byrne AT, Gaillard CA, van Solinge WW, Schiffelers RM.

Exp Hematol. 2010 Apr;38(4):282-91. doi: 10.1016/j.exphem.2010.02.001. Epub 2010 Feb 8.

PMID:
20146933
45.

Recent advances in molecular imaging biomarkers in cancer: application of bench to bedside technologies.

van der Meel R, Gallagher WM, Oliveira S, O'Connor AE, Schiffelers RM, Byrne AT.

Drug Discov Today. 2010 Feb;15(3-4):102-14. doi: 10.1016/j.drudis.2009.12.003. Epub 2009 Dec 24. Review.

PMID:
20035896
46.

Bioluminescent imaging: a critical tool in pre-clinical oncology research.

O'Neill K, Lyons SK, Gallagher WM, Curran KM, Byrne AT.

J Pathol. 2010 Feb;220(3):317-27. doi: 10.1002/path.2656. Review.

PMID:
19967724
47.

Vascular-targeted photodynamic therapy with BF2-chelated Tetraaryl-Azadipyrromethene agents: a multi-modality molecular imaging approach to therapeutic assessment.

Byrne AT, O'Connor AE, Hall M, Murtagh J, O'Neill K, Curran KM, Mongrain K, Rousseau JA, Lecomte R, McGee S, Callanan JJ, O'Shea DF, Gallagher WM.

Br J Cancer. 2009 Nov 3;101(9):1565-73. doi: 10.1038/sj.bjc.6605247. Epub 2009 Oct 13.

48.

Porphyrin and nonporphyrin photosensitizers in oncology: preclinical and clinical advances in photodynamic therapy.

O'Connor AE, Gallagher WM, Byrne AT.

Photochem Photobiol. 2009 Sep-Oct;85(5):1053-74. doi: 10.1111/j.1751-1097.2009.00585.x. Epub 2009 Aug 3. Review.

PMID:
19682322
49.

Embryonal rhabdomyosarcoma as a second malignancy following multimodal therapy for advanced-stage neuroblastoma.

Mann GS, Byrne AT, Nadel HR, Bray H.

Pediatr Radiol. 2008 Sep;38(9):1017-20. doi: 10.1007/s00247-008-0905-y. Epub 2008 Jul 2.

PMID:
18594803
50.

Imaging and intervention of retroperitoneal fibrosis.

Geoghegan T, Byrne AT, Benfayed W, McAuley G, Torreggiani WC.

Australas Radiol. 2007 Feb;51(1):26-34. Review.

PMID:
17217486

Supplemental Content

Loading ...
Support Center